Radiation therapy can treat lung cancer at all stages, easing symptoms, improving precision and minimizing side effects with ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

Triple therapy for COPD is more likely to offer cardiopulmonary benefits vs dual therapy, as indicated by NNT estimates for key cardiac outcomes.

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of treatment.

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...

For initial treatment of symptomatic pulmonary sarcoidosis, methotrexate appeared to work as well as prednisone over 24 weeks ...

"These lasers only making me younger and cuter … sorry fellas," he recently posted on Instagram, along with a video of himself receiving hyperbaric oxygen therapy (HBOT) along with a laser ...

has a deep understanding of the complexities of thoracic cancers. At the conference, he participated in the debate on the topic of - N2 disease neoadjuvant therapy vs surgery. N2 is a medical term ...